Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nantkwest Inc    NK

NANTKWEST INC (NK)
Add to my list  
Mes dernières consult.
Most popular
Manage my lists
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/13/2018 04/16/2018 04/17/2018 04/18/2018 04/19/2018 Date
3.81(c) 4.01(c) 4.22(c) 4.11(c) 4.03 Last
116 750 149 430 203 241 83 537 71 279 Volume
-0.78% +5.25% +5.24% -2.61% -1.95% Change
More quotes
Financials (USD)
Sales 2018 0,07 M
EBIT 2018 -119 M
Net income 2018 -118 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,07 M
EBIT 2019 -134 M
Net income 2019 -133 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 4 922x
Capi. / Sales2019 4 922x
Capitalization 325 M
More Financials
Company
NantKwest, Inc. is a next generation clinical-stage immunotherapy company, which engages n the development and production of cancer treatment products.Its products are based on its proprietary natural killer (NK) cell line, NK-92.The firm operates through the following geographical segments: United... 
Read more
More about the company
Surperformance© ratings of Nantkwest Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on NANTKWEST INC
04/18NANTKWEST, INC. (NASDAQ : NK) Files An 8-K Departure of Directors or Certain Off..
AQ
04/17NANTKWEST, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
03/14NANTKWEST : to Present at Upcoming Investment and Healthcare Conferences
BU
03/12NANTKWEST : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
02/13NANTKWEST : nbsp;and Frankfurt University Hospital Announce First in Human Dosin..
BU
01/05NANTKWEST : to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number..
BU
2017NANTKWEST : to Present Data at the 59th Annual Meeting of the American Society o..
AQ
2017NANTKWEST INC : Update in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) S..
AC
2017NANTKWEST : to Present Data at the 59th Annual Meeting of the American Society o..
BU
2017NANTKWEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/18NantKwest $NK Earns News Sentiment Rating of -0.14  
04/18$NK Imerys S.A.: Moodys comments on Imerys talc related law suit in the US: .. 
04/18#NK leader meets #Chinese official again, discusses improving ties #NorthKore..
1
04/17M&A daily wrap: Charlesbank, Partners Group, Hearthside, Blackstone, Patr..
3
04/16Dr. Patrick Soon-Shiong opens his remarks with staff of the with an inside j..
10
More tweets
Qtime:60
News from SeekingAlpha
04/02NantHealth Has Turned A Corner 
03/20Unum Therapeutics Updates Proposed IPO Terms 
02/15YOUR DAILY PHARMA SCOOP : Achaogen Update, Catabasis' Positive Results, Bristol-.. 
02/13Early-stage study underway assessing Nantkwest's HER2.taNK in brain cancer; s.. 
2017Forensic Analysis Value Stock Selections - December 
Chart NANTKWEST INC
Duration : Period :
Nantkwest Inc Technical Analysis Chart | NK | US63016Q1022 | 4-Traders
Technical analysis trends NANTKWEST INC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 3,00 $
Spread / Average Target -27%
EPS Revisions
Managers
NameTitle
Patrick Soon-Shiong Chairman & Chief Executive Officer
Barry J. Simon President, COO, Director & CAO
Richard J. Tajak Chief Financial Officer
Dvorit Samid Senior Vice President-Medical Affairs
Steven Gorlin Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
NANTKWEST INC-8.46%325
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB15.65%12 876
BEIGENE LTD (ADR)73.08%9 059
4-traders.com :
About :
Stay Connected :
Partners :
Copyright © 2018 Surperformance. All rights reserved.